Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

31Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

In this phase 2 multicenter study, we evaluated the efficacy and safety of li-fileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non–small cell lung cancer (mNSCLC) who had received prior immuno-therapy and progressed on their most recent therapy. The median number of prior systemic therapies was 2 (range, 1–6). Lifileucel was successfully manufactured using tumor tissue from different anatomic sites, predominantly lung. The objective response rate was 21.4% (6/28). Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1–negative, low tumor mutational burden, and STK11 mutation. Two responses were ongoing at the time of data cutoff, including one complete metabolic response in a PD-L1−negative tumor. Adverse events were generally as expected and manageable. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy.

References Powered by Scopus

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

23412Citations
N/AReaders
Get full text

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

2114Citations
N/AReaders
Get full text

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1778Citations
N/AReaders
Get full text

Cited by Powered by Scopus

EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models

1Citations
N/AReaders
Get full text

T cells lead the charge against solid tumors

1Citations
N/AReaders
Get full text

Advances in cell therapy: progress and challenges in hematological and solid tumors

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schoenfeld, A. J., Lee, S. M., Doger de Spéville, B., Gettinger, S. N., Häfliger, S., Sukari, A., … He, K. (2024). Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery, 14(8), 1389–1402. https://doi.org/10.1158/2159-8290.CD-23-1334

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

67%

Researcher 3

20%

Professor / Associate Prof. 2

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

42%

Biochemistry, Genetics and Molecular Bi... 7

37%

Earth and Planetary Sciences 2

11%

Agricultural and Biological Sciences 2

11%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 4

Save time finding and organizing research with Mendeley

Sign up for free